Get signals before everyone else does
Cut through endless headlines. See which stories and themes are gaining traction so you know what to read first—without a terminal or a research team.
Two free tools, no account and no card. Subscribe once and the signals come to you — in your inbox and on Telegram.
Start free in seconds — pick one, or both
Platform-run Stage 2 setups, breakouts and fundamentals. Subscribe once; results hit your inbox.
You choose the exact tickers and tags — we send a daily PDF of just their news, summaries and market impact, an hour before the open. Built around your watchlist, no one else’s.
See it first
A genuine sample of each free tool — the morning briefing PDF and the latest momentum screening. Download either, no account needed.
How it works
Track narratives as they build—AI infrastructure, rate expectations, energy policy—before they become headlines everywhere.
Get a clear picture of which companies sit closest to a story so you know where to look, not just what happened.
Filter by the factors you care about—growth, value, sector, risk—and keep your process consistent without manual spreadsheets.
Why it works
You don't need a desk full of monitors. Follow themes, see exposure, and narrow ideas—before the market has already moved.
Cut through endless headlines. See which stories and themes are gaining traction so you know what to read first—without a terminal or a research team.
Turn "what's everyone talking about?" into "what might affect the names in my brokerage or IRA?"—before the connection is obvious everywhere else.
Whether you check in daily or on weekends, less doom-scrolling, fewer "what did I miss?" moments, and a shorter path from headline to decision.
What you get
Watch how narratives build over time so you're not reacting to every headline in isolation—or missing the ones that actually matter.
Get a clear picture of which companies and industries sit closest to a story—before the market has priced it in.
Focus on the factors that matter to you—growth, value, risk, sectors—and keep your process consistent without spreadsheets you maintain by hand.
Free market screenings
Platform-managed screenings — Stage 2 setups, technicals, fundamentals — run on a schedule. Subscribe once and the results land in your inbox and Telegram, no setup required.
Stocks positioned to benefit from an Iran / Strait-of-Hormuz supply shock — oil & gas, oil services, defense & aerospace, tankers & shipping, uranium & energy security, and safe-haven — each validated by price momentum and real crisis-news exposure.
View screening →The short-side inverse of NIS Momentum, applying Minervini SEPA / O'Neil CAN SLIM to the SHORT side. Targets FORMER LEADERS rolling over into a Stage-4 decline — distribution and failure — not perennial losers already at new lows. The whole screen is gated on a bearish market regime (only runs when the S&P is below its 200-day). Pipeline: 0. Market regime gate: skip entirely unless the S&P 500 is below its 200-day MA. 1. Universe: all listed NYSE + NASDAQ tickers. 2. Inverted pre-screen: actively traded, price < SMA200, SMA50 < SMA200, at least 25% below the 52-week high, AND weak RS (bottom ~30%, RS < 30). 3. Stage-4 decline template — all conditions required: • close < SMA50 < SMA150 < SMA200 • SMA200 falling (20-day slope confirmation) • close at least 25% below the 52-week high, and that high is stale (made months ago — peak at least ~5 weeks old) • RS weak (RS < 30 — the inverse of the long side's RS > 70) 4. Former-leader gate (most important): ran 100%+ from a prior trough into its peak over the last 1–3 years, and the peak is at least ~5 weeks old (O'Neil: best shorts are 5–15 weeks after the top, not at the peak). 5. Distribution volume: down-days heavier than up-days over 50 sessions (up/down-volume ratio at or below 0.85 — the inverse of accumulation). 6. Decelerating fundamentals: EPS momentum not accelerating AND (EPS SMA turning down OR a recent earnings miss) — deceleration/disappointment, not absolute badness. 7. Liquidity floor: enough average daily dollar volume to borrow and exit. 8. A ticker is reported only if it passes EVERY technical AND fundamental gate. Output includes the symbol, sector, sub-sector, RS, all Stage-4 technical flags, former-leader/timing metrics (prior-advance %, % below the high, peak age, distance to the declining 50-day = overhead resistance), volume/liquidity, and the deceleration fundamental flags. Squeeze risk (high short interest / days-to-cover) and the exact rally-into-resistance entry are assessed downstream by the AI analysis pass.
Pricing
Price increases every 100 subscribers. Early subscribers lock in their rate forever.
$99/yr · lock in forever
Real-time screening, locked at this price for life.
Your price is locked for life. Cancel any time — but once you cancel, the founder rate is gone.
Straight answers
Retail and self-directed investors who manage their own accounts—taxable brokerage, IRA, or both—and want news tied to opportunities, not noise.
Most screeners start with static filters. News Impact Screener starts with what's happening in the world and shows what it might push on in the market—so you're not the last to know.
What would it mean to catch major news before everyone else? Less scrambling, fewer "I should have seen that coming" moments, and a watchlist you actually understand.
Early access
It seems like you want fast, reliable insight—without digging through hours of news. Join the list and get signals before the market reacts. Built for people who invest their own money and want context, not chaos.
Free. No spam. Takes 30 seconds.
| Symbol | Sector | Sub Sector | RS Rank |
|---|---|---|---|
| ALRS | Financial Services | Banks - Regional | 86 |
| BNY | Financial Services | Investment - Bank… | 86 |
| ECO | Industrials | Marine Shipping | 86 |
| EXEL | Healthcare | Biotechnology | 86 |
| FSBC | Financial Services | Banks - Regional | 86 |
| LQDT | Consumer Cyclical | Specialty Retail | 86 |
| MUSA | Consumer Cyclical | Specialty Retail | 86 |
| TDC | Technology | Software - Infras… | 86 |
Daily regime reads, top-story breakdowns, and watchlist setups — the screener's signal, in 30 seconds a day.

A fintech you’ve never heard of more than doubled while the market barely moved — and it’s breaking out again. $SEZL: +135% vs the S&P’s +6%. Buy-now-pay-later, and it’s everywhere now. Profits doubled in a year, 4 straight earnings beats. Entry 170, target 198. Loses the 50-day, you’re out. Not advice. But the screener that flagged it 👉 newsimpactscreener.com
View
A boring factory-parts maker just beat the market 10 to 1 — and it’s coiled to break out again. $NPO: +70% vs the S&P’s +6%. Makes the seals and coatings that keep factories and chip plants running. Unsexy, essential. Almost 6x normal volume today — biggest day in months. Not a buy yet. Clears 390 on volume, target 434. Loses the 50-day, you’re out. Not advice.
View
A “boring” drug stock quietly beat the entire market and it’s one push from breaking out. $AMRX: +34% vs the S&P’s +6%. Profits up 73%. 5 straight earnings beats. 4x volume today. The level to clear is 17.77. That’s the whole trade. Not advice.
View
When everbody else is buying graphic cards and memory chips, I am buying chain and couches to watch the mayhem unfold 🧌🚀 I shared the $HOFT early breakout 6 days ago on June 16, and today it broke out and I entered. Follow along to receive the same breakout that I do!
View
Liquidia printed 6× its normal volume into its pivot — RS 97, top 3% of the market. $LQDA is one of the strongest relative-strength leaders in the entire market right now, and it just did something that's hard to ignore: it traded more than six times its average volume in a single session, pressing right up under a clean pivot at 73.22. Here's the mechanism. After months of basing, the stock ran roughly 80% in six weeks and is now coiled just 3% under its breakout level — and the volume tells you who's behind it. Up-down volume is nearly 3 to 1, the signature of institutions accumulating, not distributing. The business turned the corner too: Liquidia just flipped from losses to profit, posting 52 cents last quarter and blowing past estimates, with EPS up triple digits year over year. The plan is mechanical. Entry on a confirmed close above 73.22. Stop at 67.36 — 8% risk. First target 84.94, a clean 2-to-1, with a runner to 90. Size to the stop, never to the excitement. Now the honest part — and it lives right here, not in the hook. This stock has already run hard, so it's a watch until it actually clears 73.22, not a chase. It's also a biotech, which means news and trial/FDA headlines can gap it in either direction. If it loses the 50-day on volume, the setup is dead, no questions. If you're still waiting for a leader to look "safe," you'll be paying up for it. The screener that flagged this is at newsimpactscreener.com. Not financial advice. For education only.
View